Evidence map›Paper›PMID 27065000›Full record

ArticleHuman vaccines & immunotherapeutics2016

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.

M Rondy, J Castilla, O Launay, S Costanzo, C Ezpeleta, F Galtier, K de Gaetano Donati, A Moren

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

M Rondya Epicon0063ept , Paris , France.
J Castillab Instituto de Salud Pública de Navarra, IdiSNA, CIBER Epidemiología y Salud Pública , Spain.
O Launayc Inserm, CIC 1417 and F-CRIN, Innovative clinical research network in vaccinologie (I-REIVAC), Université Paris Descartes; Sorbonne Paris Cité ; Paris , France.
S Costanzod Department of Epidemiology and Prevention , IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (Isernia) , Italy.
C Ezpeletae Service of Clinical Microbiology, Complejo Hospitalario de Navarra, IdiSNA , Pamplona , Spain.
F Galtierf CHRU de Montpellier, Inserm, CIC 1411 and REIVAC , Montpellier , France.
K de Gaetano Donatig Department of Infectious Disease , Catholic University , Rome , Italy .
A Morena Epicon0063ept , Paris , France.
Amplitude Technologies (France) · FRClinical Investigation Center Plurithematic Tours · FRComplejo Hospitalario de Navarra · ESInstituto de Salud Pública de Navarra · ESIstituto Neurologico Mediterraneo · ITUniversità Cattolica del Sacro Cuore · ITUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a multicentre test negative case control study to estimate the 2013-14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: -1.9;85.4), 39.4% (95%CI: -32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18-64, 65-79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: -145.3;65.4), 25.6% (95%CI: -36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18-64, 65-79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013-14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeAdolescentAdultAgedAged, 80 and overCase-Control StudiesEuropean UnionFemaleFranceHospitalizationHumansInfluenza, HumanInfluenza VaccinesItalyLogistic ModelsInfluenza Vaccinescase control studieshospitalInfluenzaInfluenza vaccinemulticentre studies

Identifiers

PMID27065000
PMCPMC5036960
OpenAlexW2316499622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.